Correlation
The correlation between EXEL and BMY is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
EXEL vs. BMY
Compare and contrast key facts about Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EXEL or BMY.
Performance
EXEL vs. BMY - Performance Comparison
Loading data...
Key characteristics
EXEL:
2.65
BMY:
0.83
EXEL:
4.02
BMY:
1.38
EXEL:
1.56
BMY:
1.17
EXEL:
1.91
BMY:
0.53
EXEL:
21.15
BMY:
2.67
EXEL:
5.28%
BMY:
9.42%
EXEL:
40.80%
BMY:
31.39%
EXEL:
-97.38%
BMY:
-70.62%
EXEL:
-12.61%
BMY:
-33.83%
Fundamentals
EXEL:
$11.74B
BMY:
$98.25B
EXEL:
$2.19
BMY:
$2.68
EXEL:
19.65
BMY:
18.01
EXEL:
2.27
BMY:
2.26
EXEL:
5.11
BMY:
2.06
EXEL:
5.51
BMY:
5.65
EXEL:
$2.30B
BMY:
$47.64B
EXEL:
$2.22B
BMY:
$31.43B
EXEL:
$844.28M
BMY:
$16.18B
Returns By Period
In the year-to-date period, EXEL achieves a 29.25% return, which is significantly higher than BMY's -12.76% return. Over the past 10 years, EXEL has outperformed BMY with an annualized return of 29.13%, while BMY has yielded a comparatively lower 0.11% annualized return.
EXEL
29.25%
8.69%
18.05%
98.43%
32.91%
11.74%
29.13%
BMY
-12.76%
-4.53%
-16.68%
23.27%
-10.29%
-0.59%
0.11%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EXEL vs. BMY — Risk-Adjusted Performance Rank
EXEL
BMY
EXEL vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
EXEL vs. BMY - Dividend Comparison
EXEL has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.05%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EXEL Exelixis, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.05% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
EXEL vs. BMY - Drawdown Comparison
The maximum EXEL drawdown since its inception was -97.38%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for EXEL and BMY.
Loading data...
Volatility
EXEL vs. BMY - Volatility Comparison
Exelixis, Inc. (EXEL) has a higher volatility of 21.93% compared to Bristol-Myers Squibb Company (BMY) at 11.13%. This indicates that EXEL's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
EXEL vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Exelixis, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EXEL vs. BMY - Profitability Comparison
EXEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Exelixis, Inc. reported a gross profit of 536.28M and revenue of 555.45M. Therefore, the gross margin over that period was 96.6%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
EXEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Exelixis, Inc. reported an operating income of 186.86M and revenue of 555.45M, resulting in an operating margin of 33.6%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
EXEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Exelixis, Inc. reported a net income of 159.62M and revenue of 555.45M, resulting in a net margin of 28.7%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.